{
    "Trade/Device Name(s)": [
        "B-type Natriuretic Peptide (BNP) Assay for the ADVIA IMS",
        "ADVIA IMS BNP Assay"
    ],
    "Submitter Information": "Bayer HealthCare LLC",
    "510(k) Number": "K051265",
    "Predicate Device Reference 510(k) Number(s)": [],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NBC"
    ],
    "Summary Letter Date": "June 13, 2005",
    "Summary Letter Received Date": "May 17, 2005",
    "Submission Date": "May 12, 2005",
    "Regulation Number(s)": [
        "21CFR862.1117"
    ],
    "Regulation Name(s)": [
        "B-type natriuretic peptide test system"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "cardiac",
        "misc"
    ],
    "Analyte(s)": [
        "B-type Natriuretic Peptide (BNP)"
    ],
    "Specimen Type(s)": [
        "Plasma"
    ],
    "Specimen Container(s)": [
        "EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "ADVIA Immuno Modular System (IMS)"
    ],
    "Method(s)/Technology(ies)": [
        "Heterogeneous sandwich immunoassay",
        "Magnetic separation",
        "Chemiluminescent enzyme immunoassay"
    ],
    "Methodologies": [
        "Immunoassay",
        "Sandwich assay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Calibrator",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for ADVIA IMS BNP assay for quantitative measurement of BNP in plasma to aid in diagnosing and assessing heart failure and risk in ACS patients",
    "Indications for Use Summary": "For in vitro quantitative determination of B-type Natriuretic Peptide (BNP) in human plasma using the ADVIA IMS System, aiding diagnosis and severity assessment of heart failure and risk prediction in acute coronary syndromes",
    "fda_folder": "Clinical Chemistry"
}